Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO INVESTORS PROSPECTUS Prospectus 2021 On February 4, 2021, Orexo issued senior unsecured callable floating rate bonds amounting to SEK 500 million, under a framework of SEK 1,000 million with final maturity in February 2025. The new bonds carry a floating rate interest of 3-month Stibor + 375bps per annum. The proceeds from the new bonds will be applied towards repayment in full of the existing bonds and general corporate purposes, to further strengthen the company's capacity and flexibility for future investments. For legal documents view here: Notice of Early redemption Notice of Waiver from Nordic Trustee & Agency AB Prospectus 2017 On November 13, 2017, Orexo issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, due in November 2021. The bond loan has a floating interest rate of STIBOR 3m +4.50 per cent per year (quarterly payments in arrears). The prospectus in relation to listing of the bond on Nasdaq Stockholm can be found here: Conditions - Redemption of senior unsecured bonds 2014 Prospectus regarding issue of a corporate bond 2011 Prospectus regarding new issue Supplementary prospectus regarding new issue 2007 Prospectus regarding initiation of Orexo AB share trade due to acquisition of Biolipox 2005 Prospectus regarding Initial Public Offering Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy

Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO ABOUT US FINANCIAL INFORMATION Financial information Key figures SEK million 2020 2019 2018 2017 2016 Net revenues 663.6 844.8 783.1 643.7 705.9 whereof ZUBSOLV® US net revenue 623.3 719.2 621.5 485.8 481.8 Cost of goods sold –65.6 –105.6 –171.8 –164.4 –149.6 Operating expenses –617.9 –508.0 –515.6 –421.9 –584.4 EBIT -19.9 231.2 95.8 57.4 51.7 EBIT margin, % -3.0 27.4 12.2 8.9 7.3 EBITDA 19.0 272.1 116.6 78.2 73.1 Earnings per share, before dilution, SEK -2.45 6.33 3.99 0.67 0.84 Earnings per share, after dilution, SEK -2.45 6.20 3.93 0.67 0.84 Cash flow from operating activities 16.8 290.9 242.0 146.6 156.2 Cash and cash equivalents 505.3 816.8 589.8 327.9 282.4 Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy